Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-24-027621
Filing Date
2024-08-22
Accepted
2024-08-22 17:04:01
Documents
14
Period of Report
2024-08-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A rvph20240822_8ka.htm   iXBRL 8-K/A 47659
  Complete submission text file 0001437749-24-027621.txt   203658

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvph-20240820.xsd EX-101.SCH 3913
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20240820_def.xml EX-101.DEF 13844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20240820_lab.xml EX-101.LAB 18247
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20240820_pre.xml EX-101.PRE 13876
16 EXTRACTED XBRL INSTANCE DOCUMENT rvph20240822_8ka_htm.xml XML 5033
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38634 | Film No.: 241232718
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)